Tumor autoantibodies in the diagnosis and prognosis of prostate cancer

VernacularTitle:肿瘤自身抗体在前列腺癌诊断和预后中的应用
Author: Ning LOU ; Yuankai SHI ; Xiaohong HAN
From: Chinese Journal of Laboratory Medicine 2021;44(3):260-264
CountryChina
Language:Chinese
Abstract: Detection of prostate specific antigen (PSA) is the most commonly used screening method for prostate cancer. However, many studies have found that the false positive rate and false negative rate of PSA detection for prostate cancer screening are very high, which easily leads to the overuse of PSA detection. Autoantibodies appear at the early stage of cancer, accompany the occurrence and development of prostate cancer. Autoantibodies have a long half-life and are easy to detect. Existing studies have found that autoantibodies can be used in the diagnosis of prostate cancer, and correlated with some prognostic indicators such as Gleason grade and overall survival (OS) of prostate cancer patients. This paper summarized 8 studies on the role of single autoantibody in the diagnosis and prognosis of prostate cancer. Most of the reported single autoantibodies have better diagnostic performance than PSA, and combined application could improve the diagnostic performance. Some autoantibodies are related to a poor prognosis of prostate cancer.